microRNA-based predictor for diagnosis of frontotemporal dementia

Short title: miRNA biomarkers for FTD

Iddo Magen[1,2,†], Nancy-Sarah Yacovzada[1,2,†], Jason D. Warren[3], Carolin Heller[3,4], Imogen Swift[3,4], Yoana Bobeva[5], Andrea Malaspina[5,6], Jonathan D. Rohrer[3], Pietro Fratta[6], and Eran Hornstein[1,2]

1   Department of Molecular Genetics, Weizmann Institute of Science, Rehovot, Israel

2   Department of Molecular Neuroscience, Weizmann Institute of Science, Rehovot, Israel

3 Dementia Research Centre, and 4 UK Dementia Research Institute, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK.

5 Centre for Neuroscience and Trauma, Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK.

6 Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, London, UK

† Equal contribution

Email addresses (order of emails corresponds to the order of authors): iddo.magen@weizmann.ac.il; nancyy@weizmann.ac.il; jason.warren@ucl.ac.uk; c.heller@ucl.ac.uk; i.swift.17@ucl.ac.uk; y.bobeva@qmul.ac.uk; a.malaspina@ucl.ac.uk; j.rohrer@ucl.ac.uk; p.fratta@ucl.ac.uk; eran.hornstein@weizmann.ac.il;

Correspondence to: Andrea Malaspina; Jonathan D. Rohrer; Pietro Fratta; Eran Hornstein.

Abstract word count: 150

Text word count (excluding title page, abstract, references and figure legends): 4394

No. of items (Figures, Tables, Supplementary): 5, 2, 6

References: 92

Abstract

Background

Frontotemporal dementia (FTD) is an early onset dementia that is diagnosed in ~20% of the progressive dementia cases. Heterogeneity in FTD clinical presentation too often delays clinical diagnosis and calls for molecular biomarkers to assist diagnosis, including cell free microRNAs (miRNA). However, nonlinearity in the relationship of miRNAs to clinical states and underpowered cohorts has limited research in this domain.

Methods

We initially studied a training cohort of 219 subjects (135 FTD and 84 non-neurodegenerative controls) and then validated the results in a cohort of 74 subjects (33 FTD and 41 controls).

Results

Based on cell-free plasma miRNA profiling by next generation sequencing and machine learning approaches, we develop a nonlinear prediction model that accurately distinguishes FTD from non-neurodegenerative controls in ~90% of cases.

Conclusion

The fascinating potential of diagnostic miRNA biomarkers might enable early-stage detection and a cost-effective screening approach for clinical trials that can facilitate drug development.

Key words: frontotemporal dementia; biomarker; microRNA; diagnosis; machine learning; non-linear relationship; next-generation sequencing; predictor; feature elimination.

Background

Frontotemporal dementia (FTD) is a neurodegenerative disease that is characterized by frontal and temporal lobe atrophy, and typically manifests with behavioral or language deficits [1-4].

The key known genetic drivers of FTD include hexanucleotide repeat expansion in the first intron of the gene chromosome 9 open reading frame 72 (*C9ORF72*) [5, 6], and mutations in the genes Valosin-containing protein (*VCP), TANK-binding kinase 1 (TBK1),* progranulin (GRN), charged multivesicular body protein 2B (CHMP2B) and the RNA-binding protein TAR DNA-binding protein 43 (TDP-43) [7-11] . Relatedly, inclusions of TDP-43 are a hallmark of FTD neuropathology [12].

FTD can be difficult to diagnose, due to heterogeneity in clinical presentation [1]. Three main phenotypes of FTD are described: behavioral variant frontotemporal dementia (bvFTD), characterized by changes in social behavior and conduct, semantic dementia (SD), characterized by the loss of semantic knowledge, leading to impaired word comprehension and progressive non-fluent aphasia (PNFA), characterized by progressive difficulties in speech production [1, 13]. Related motor variants within the FTD spectrum are corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP) [14]. FTD further resides on a genetic and a clinico-pathological continuum with amyotrophic lateral sclerosis (ALS) [15].

Brain imaging and several biofluid proteins have been proposed as biomarkers for FTD [16-45]. Among the proteins, noticeable are neurofilament light chain (NfL), TDP-43, and phospho-tau, amyloid beta and glial fibrillary acidic protein (GFAP). A recent study concluded that high NfL blood levels are indicative of the intensity of neurodegeneration or the extent of the degenerated axons in FTD [24].

microRNAs (miRNAs) are a class of small, non-coding RNAs, that can be quantified in biofluids in a massively parallel fashion, yielding fine-grained profiles [46]. We have previously shown the power of cell-free miRNAs as biomarkers in neurodegeneration [47, 48]. Plasma miRNAs were suggested as diagnostic biomarkers for FTD [49-57].

However, initial biomarker studies were confounded by cohort size, sample heterogeneity biases or pre-selection of candidate miRNAs. Furthermore, these studies did not address the potential non-linear relationships between miRNAs in developing a predictor.

In the current study, we profiled blood plasma miRNAs, and developed miRNA-based classifier for diagnosing FTD in a training cohort of 219 subjects, that was further validated in a cohort of 74 subjects. We implemented an ensemble machine learning approach, to address biomarker

nonlinearity and were able to expose unrevealed disease-associated signals. We then
confirmed that these signals are similar between clinical subtypes of FTD. The diagnostic power
of the study roots from unbiased miRNA signature discovered by advanced machine learning,
on a large and heterogeneous cohort, and validation in an independent held-out cohort,
according to the TRIPOD guidelines [58]. Therefore, circulating miRNAs hold a fascinating
potential as diagnostic biomarkers and as means for patient stratification in clinical trials.

Methods

Participants and Sampling

Demographic data of study participants are detailed in Table 1.

FTD subjects and their respective controls were enrolled in the longitudinal FTD cohort studies at UCL. Study cohort included 169 FTD patients and 56 controls. Additional controls (N=102) were obtained from the ALS biomarker study (Ethics approval 09/H0703/27) in Queen Mary Hospital, totaling 158 non-neurodegenerative controls. Controls were typically spouses or relatives of patients.

Blood was collected by venipuncture in EDTA tubes, and plasma was recovered from the whole blood sample by centrifugation for 10 minutes at 3500 RPM at 4°C within 1 hour of sampling, and stored at –80°C until RNA extraction and subsequent small RNA next generation sequencing. Frozen plasma samples of FTD and controls from the UCL Biobanks were shipped to the Weizmann Institute of Science for molecular analysis.

Study Design

We determined the sample size by the following power analysis: 150 controls and 150 cases are required to obtain an ROC AUC of 0.7 with a power of 99% and a p-value of 0.0001. Phenotypic data on de-identified patients was separated and blinded during steps of the molecular analysis.

Small RNA Next Generation Sequencing

Total RNA was extracted from plasma using the miRNeasy micro kit (Qiagen, Hilden, Germany) and quantified with Qubit fluorometer using RNA broad range (BR) assay kit (Thermo Fisher Scientific, Waltham, MA). For small RNA next generation sequencing (RNA-seq), libraries were prepared from 7.5 ng of total RNA using the QIAseq miRNA Library Kit and QIAseq miRNA NGS 48 Index IL (Qiagen), by an experimenter who was blinded to the identity of samples. Samples were randomly allocated to library preparation and sequencing in batches. Precise linear quantification of miRNA is achieved by using unique molecular identifiers (UMIs), of random 12-nucleotide after 3' and 5' adapter ligation, within the reverse transcription primers [46]. cDNA libraries were amplified by PCR for 22 cycles, with a 3' primer that includes a 6-nucleotide unique index, followed by on-bead size selection and cleaning. Library concentration was determined with Qubit fluorometer (dsDNA high sensitivity assay kit; Thermo Fisher

Scientific, Waltham, MA) and library size with Tapestation D1000 (Agilent). Libraries with
different indices were multiplexed and sequenced on NextSeq 500/550 v2 flow cell or Novaseq
SP100 (Illumina), with 75bp single read and 6bp index read. Fastq files were de-multiplexed
using the user-friendly transcriptome analysis pipeline (UTAP) [59]. Human miRNAs, as defined
by   miRBase   [60],   were   mapped   using   the   GeneGlobe   pipeline
(https://geneglobe.qiagen.com/us/analyze). For quality control of sequencing data, we first
excluded miRNAs with an average UMI counts < 100 across all samples or zero count in at
least one sample. Data were further corrected for the library preparation batch in order to
reduce its potential bias, and normalized with DESeq2 package [61] under the assumption that
miRNA counts followed negative binomial distribution

Constructing Cohorts and Age and Sex Biases

We observed a younger mean age in controls (53.8±14.5, 95% CI [51.5- 56.1]) than in FTD
(65.6±8.4, 95% CI [64.4-67.0], Table S1). We reduced age-variance by excluding 34
participants younger than 40, which reduced differences in mean age across the remaining
meta-cohort of 293 subjects by 45%. Thus, 168 out of 169 FTD patients and 125 out of 158
non-neurodegenerative control samples were included in the analysis (Table S1). In order to
verify that a merged dataset of controls, collected in two different clinical centers, does not
introduce biases, we employed the t-distributed stochastic neighbor embedding (t-SNE)
algorithm and measured Kullback–Leibler divergence, the difference between probability
distributions. Because a higher prevalence of males was observed among FTD patients (65%)
than among the controls (35%), sex was removed from the list of candidate predictors to
eliminate confounding biases.

Gradient Boosted Trees for the Development of Disease Binary Classifiers

The FTD-disease binary classifier was developed using Gradient Boosting Classifier, a
machine-learning algorithm that uses a gradient boosting framework. Diagnostic models were
developed, validated and reported according to the TRIPOD guidelines [58] (https://www.tripod-
statement.org/). Gradient Boosting trees [62, 63], a decision-tree-based ensemble model, differ
fundamentally from conventional statistical techniques that aim to fit a single model using the
entire dataset. Such ensemble approach improves performance by combining strengths of
models that learn the data by recursive binary splits, such as trees, and of "boosting", an
adaptive method for combining several simple (base) models. At each iteration of the gradient
boosting algorithm, a subsample of the training data is selected at random (without

replacement) from the entire training data set, and then a simple base learner is fitted on each
subsample. The final boosted trees model is an additive tree model, constructed by sequentially
fitting such base learners on different subsamples. This procedure incorporates randomization,
which is known to substantially improve the predictor accuracy and also increase robustness.
Additionally, boosted trees can fit complex nonlinear relationships, and automatically handle
interaction effects between predictors as addition to other advantages of tree-based methods,
such as handling features of different types and accommodating missing data. Hence, in many
cases their predictive performance is superior to most traditional modelling methods. Additional
gain of these algorithms is the various loss functions that can be applied. Using the softmax loss
function, we explicitly estimated the class conditional probabilities, which allow us to
demonstrate the performance of each of the classifiers both as "soft-classifiers" (i.e., predicting
class probabilities) and "hard-classifiers" (i.e., setting a probability threshold and predicting a
class). The former approximates a continuous number as output - the class conditional
probabilities - and then performs classification based on these estimated probabilities. In
contrast, hard classifiers output a discrete number as the decision - directly targeting the
classification decision boundary, without producing the probability estimation.

A gradient boosting classifier was developed with a feature set of 132 miRNA predictors.
Dataset was partitioned to training-set (75%) and validation-set (25%) which was used as held-
out data. The training-set was cross-validated during training with stratified 3-fold cross
validation. An ROC was generated for each of the folds and individual and mean AUCs were
calculated along with 95% confidence intervals.
The chosen hyper-parameters: ccp_alpha=0.0, learning_rate=0.5, max_depth=8,
max_features=0.45, min_samples_leaf=14, min_samples_split=8, n_estimators=100,
subsample=0.45 and tol=0.0001.

miRNA Predictor Selection by Recursive Feature Elimination (RFE)

For selecting the most predictive features during prediction model development, we used
Recursive Feature Elimination (RFE) algorithm, an efficient recursive approach for eliminating
features from a training dataset with 3-fold cross validation. ExtraTreesClassifier algorithm is
used in the cross-validated RFE procedure, with hyper-parameters: criterion="entropy",
max_features=0.9, and n_estimators=20. RFE works by iteratively removing features and using
model accuracy to identify which features contribute the most to prediction. Tree-based

importance scores of 132 miRNAs were used in order to rank features, and thus reduce the
dimension of miRNA measurements needed for prediction by ~90% (12-16 features in a model
in total).

Feature Importance and SHAP Analysis

Although gradient boosting tree models are complex models, they can automatically provide an
approximation of feature importance from the trained boosted trees. A miRNA predictor is
assigned with an importance score in every single tree, where the Gini purity index is used to
assess split points in the tree. The score of a feature is calculated based on the amount of
improvement in the Gini index achieved by split points that include the feature, weighted by the
number of observations in that node. The final importance score of a feature is calculated by an
average across all decision trees within the final model.

For local interpretability of the predictive model, we used SHapley Additive exPlanations (SHAP)
[64], the current state of the art in Machine Learning explainability tools. SHAP provides
estimates and visualizations to infer what decisions the model is making. This is achieved by
quantifying the contribution that each feature brings to each prediction made by the model.

Linear regression model

A linear classifier (Logistic Regression) was developed with a feature set of 95 miRNA
predictors, that were differentially expressed (adjusted p-value ≤ 0.05) between FTD cases and
controls. Each miRNA was binarized by its mean value. Training and validation were identical
as in the gradient boosting classifier: Dataset was partitioned to training-set (75%) and
validation-set (25%) which was used as held-out data. The training-set was cross-validated
during training with stratified 3-fold cross validation. An ROC was generated for each of the
folds and individual and mean AUCs were calculated along with 95% confidence intervals. The
chosen hyperparams for Logistic Regression: L2 penalty, tol=1e-4, fit_intercept=True,
solver='lbfgs', max_iter=500.

Results

We sought to determine the overall diagnostic capability of miRNA measurements in FTD. To
this end, we based our study on analysis of plasma miRNA expression and the development of
computational diagnostic models. The cohort included a total of 293 participants, enrolled
between 2009 and 2018. Summary of participants' basic characteristics is shown in Table 1.

Since the non-neurodegenerative controls were collected in two centers, we first verified that
they could have been sampled from a single population and can therefore be considered a
single cohort. We estimated the Kullback–Leibler divergence, a measure of the difference
between two probability distributions. This analysis indicated only a small difference between
the two sets in question (KL = 0.293, Figure S1), that is further visualized by t-distributed
stochastic neighbor embedding (t-SNE) analysis of the cohorts.

Differential expression of miRNAs

Out of the >2000 miRNA species that were aligned to the genome, only 132 fulfilled QC criteria
(see methods). Next, we quantified the differential miRNAs that may distinguish FTD from
controls. Ninety-five miRNAs were differentially expressed between plasma of patients with FTD
and controls with an adjusted p-value<0.05 (Figure 1A). Additional analysis of only subsets of
C9ORF72-FTD cases (Figure 1B), FTD females (Figure 1C) or FTD males (Figure 1D) vs.
relevant controls revealed that the miRNA signature was comparable between the full FTD
cohort and subcategories (Table S2: Source Data Fig. 1).

Development of machine learning classifier for the diagnosis of FTD

We established a diagnostic prediction model for FTD on a randomly selected training set of
135 FTD cases and 84 controls, comprising 75% of the total cohort (168 cases, 125 controls).
For model validation, the remaining 25% of the data were held out as a replication cohort (33
FTD, 41 control samples).

The 132 miRNAs were tested as potential predictors, using an ensemble machine learning
approach for ranking miRNAs predictive value in the diagnosis of FTD vs. individuals that did
not suffer from neurodegeneration and were considered healthy. For selecting the most
predictive features during model development, we used Recursive Feature Elimination (RFE),
an efficient approach that removes miRNAs (features) iteratively to identify those that contribute
the most to prediction accuracy. Cross validated RFE on the training set with gradient boosting
classifier obtained a set of 13 miRNAs with highest feature importance (Figure 2A). The 13-
miRNA-based prediction model presented a mean receiver operating characteristic area under
the curve (ROC AUC) of 0.93 under internal cross validation on training dataset (Figure 2B).
Furthermore, the 13-miRNA-based predictor was capable of predicting the diagnosis of FTD in
an independent held-out (replication) cohort of 74 individuals with an ROC AUC of 0.9 (Figure
2C). At a defined probability threshold (0.6), the classifier exhibits a 0.8 precision (PPV) over
0.87 negative predictive value (NPV) with a 0.85 recall (sensitivity), a 0.83 specificity and a 0.13

false omission rate over 0.2 false discovery rate values (Figure 2D). Additional analysis reveals that the model is well calibrated and satisfactorily performs on held-out data (Figure 2E). Furthermore, a family of models trained with only a subset of the 13 most predictive features, displays a stable AUC ROC performance and reassures that the selected final features are suitable (Figure 2F). In summary, we determined 13 miRNAs that are able to call the diagnosis of FTD with high accuracy. We have further compared the machine-learning based model to a linear model classifier based on logistic regression. A linear model that was developed with a feature set of 95 miRNAs that were differentially expressed between FTD and controls, was inferior to the gradient boosting classifier model, particularly by sensitivity (0.76 vs 0.85) and negative predictive value (0.81 vs 0.87) (Figure S2). Moreover, the non-linear approach showed better robustness in the different training folds and also outperforms the linear model in utilizing a significantly smaller number of miRNA features (13 vs. 95), to obtain its accuracy.

We then sought to better understand the prediction model by investigating the relative effect of each individual miRNA. Therefore, we utilized post-hoc SHapley Additive exPlanations (SHAP) feature importance analysis to uncover the contribution of individual miRNAs to the FTD diagnostic predictor (Figure 3A, B). A more positive or more negative SHAP value leads the model to a more likely FTD or healthy control predictions, respectively. The key predictors revealed by SHAP, which contribute the most to calling FTD vs controls, are multiple sclerosis-associated miR-629 [65, 66], brain enriched miR-125b [67] and the astrocyte-derived exosomal miR-361 [68].

We further tested each individual miRNA as a single predictor of FTD diagnosis. A model with only miR-423-5p or miR-125b-5p presented the highest AUC values of ~0.69 (Table 2). Boxplots depicting the underlying distribution of each of the 13 miRNA predictors, along with scatter plots of the expression values of individual subjects in these miRNAs, confirm the non-linear relationship between miRNA expression and the phenotype, for some miRNAs (e.g., miR-107 and miR-26a), while other miRNAs can be divided to low/high values predominated by either controls or FTD cases (e.g., miR-629-5p, Figure 4). These observations emphasize the power of a model, which is able to take into account non-linear relationship between features.

Significant pairwise differences were noted in miR-107 levels in both bvFTD and SD vs other FTD subtypes [(primary progressive aphasia, corticobasal syndrome, progressive supranuclear palsy and FTD with motor neuron disease). ANOVA: p=0.009, bvFTD vs other FTD subtypes: p=0.01, SD vs other FTD subtypes: p=0.02, Figure S3C]. In addition, significant pairwise

differences in miR-26a levels were found in both bvFTD (p=0.04) and PNFA (p=0.02) vs other

FTD subtypes (ANOVA: p=0.024, bvFTD vs other FTD subtypes: p=0.04, PNFA vs other FTD

subtypes: p=0.02, Figure S3F).

None of the other miRNAs showed differences between clinical subtypes (Figure S3), between

different mutation carriers, or between mutations carriers and patients with no known FTD

mutations (Figure S4). In conclusion, a non-linear signature based on only 13 miRNAs is able to

call the diagnosis of FTD with high accuracy and generalizability, for all FTD subtypes and

independent of the underlying genetic background.

Finally, we tested the performance of plasma miRNA classifiers that were reported in previous

works [52, 54], relative to the classifier we have reported here. We replicated the logistic

regression model (with L2 regularization[69, 70]) from the study of [54] on our data. Taking miR-

34a-5p, miR-345-5p, miR-200c-3p and miR-10a-3p as features, displayed inferiority to our

model. Moreover, these miRNAs were not differentially expressed between cases and controls

in our study. Next, we replicated the "microRNA pair" approach from the study of [52]: miR-

335/let-7e, miR-99b/let-7e and miR-9-3p/miR-181a and assessed the ROC curves, showing

they are inferior to our classifier in distinguishing between FTD and controls (Figure 5). Thus,

when tested in comparison to reported miRNA classifiers from the literature, our panels of

miRNA classifiers perform better, with AUC values of 0.9.

Discussion

The need to facilitate the diagnosis of FTD in the face of clinical heterogeneity raises the hope for new effective biomarkers. Circulating miRNAs hold a fascinating potential as diagnostic biomarkers that were not fully explored. By using an unbiased, next generation sequencing approach and advanced computation, in a discovery cohort of 219 subjects and 74 additional subjects for a replication study, we overcome limitations of past works in developing biomarkers for FTD. A recursive non-linear approach was utilized to find the smallest set of miRNA features that obtain the highest accuracy of the prediction model, leading to a signature of 13 miRNAs only. Thus, our miRNA-based binary classifier is more accurate and robust than published miRNA-based predictors [52, 54].

The use of gradient boosting trees, an ensemble learning approach, allows discovering nonlinear relationships between miRNAs and disease status that gained affirmation by cross validation in the training dataset. Furthermore, our model is externally validated on held-out data, which was not used during feature selection and model development, according to the TRIPOD guidelines [58]. SHAP analysis [64] further unfolds the relative contribution of individual features to the predictive model. Of note, the performance of the ensemble learning was superior to that of a logistic regression model, and enabled the use of only 13 features, instead of 95, for prediction.

According to the human miRNA tissue atlas [67], most of the selected miRNAs are CNS-enriched (let-7c-5p, miR-26a-5p, miR-107, miR-125b-5p), suggesting that they might be directly involved in the disease state of the CNS. miR-26a, miR-326, miR-484 and miR-361 were associated with FTD diagnosis in our data and with cognitive deficits or Alzheimer's disease (AD) in other analyses [71-77]. In mice, miR-326 inhibited tau phosphorylation, a hallmark of FTD [72]. Brain-enriched miR-107 was also implicated in AD [78-83]. Changes in blood levels of miR-326, miR-26a, and miR-629 are associated with multiple sclerosis (MS), a condition characterized by demyelination [84-91]. Moreover, serum miR-629 was negatively correlated with MS patient brain volume and lesion severity, respectively [92]. Thus, some of the miRNA predictors proposed here are associated directly or indirectly with other degenerative brain diseases.

We would like to put forward a few notable limitations of our study: First, patients in our cohorts
are recruited in different phases of the disease, with no progression biomarker to use for
stratification. Second, the study of biomarkers by machine learning leaves the question why
defined nonlinear patterns are strongly predictive of disease states, unanswered. Discrepancies
from the conclusions of past studies [49-52, 54] are plausibly related to the progress we present
in power (larger cohort) and to our unbiased analysis that contrasts past biased choices of
miRNA candidates. In addition, we did not find any miRNAs, which can differentiate between
FTD subtypes, which might result from small, underpowered subtype cohorts. Lastly, while we
kept a held-out cohort for external validation, towards clinical diagnostic usage, it is warranted to
test the predictor on an independent cohort of different ethnicity.

Conclusions

We have found specific molecular miRNA patterns that can contribute to the diagnosis of FTD.
Therefore, the work encourages testing if circulating miRNAs biomarkers can be used as a cost-
effective screening approach to increase speed or precision in the diagnosis of suspected FTD.
Early-stage diagnosis may be useful towards design of prospective clinical trials. More broadly,
the findings demonstrate the importance of integrating machine learning into clinical biomarker
studies, addressing nonlinearity and exposing otherwise cryptic disease-associated signals.

List of abbreviations

AD, Alzheimer's Disease; ALS, amyotrophic lateral sclerosis; AUC, area under the curve;
bvFTD, behavioral frontotemporal dementia; C9ORF72, chromosome 9 open reading frame 72;
CBS, corticobasal syndrome; CHMP2B, charged multivesicular body protein 2B; EDTA,
Ethylenediaminetetraacetic acid; FTD, frontotemporal dementia; GFAP, glial fibrillary acidic
protein; GRN, progranulin; MAPT, microtubule-associated protein tau; miRNA, microrRNA; MS,
multiple sclerosis; NfL, neurofilament light chain; PNFA, progressive non-fluent aphasia; PSP,
progressive supranuclear palsy; ROC, receiver operating characteristic; RFE, recursive feature
elimination; SD, semantic dementia; SHAP, SHapley Additive exPlanations; TBK1, TANK-
binding kinase; TDP-43, TAR DNA-binding protein 43; TRIPOD, Transparent reporting of a
multivariable prediction model for individual prognosis or diagnosis; UMI, unique molecular
identifier; UTAP, user-friendly transcriptome analysis pipeline; VCP, Valosin-containing protein;

Declarations

Ethical Approval and Consent to participate

Approvals were obtained from the local research ethics committee and all participants provided written consent (or gave verbal permission for a carer to sign on their behalf).

Consent for publication

Not applicable.

Availability of supporting data

The data that support the findings of this study are available from the corresponding author upon reasonable request.

Competing interests

The authors state that they have no competing interests.

Funding

Research at the Hornstein laboratory is supported by the CReATe consortium and ALSA (program: "Prognostic Value of miRNAs in Biofluids From ALS Patients"), the RADALA Foundation; AFM Telethon (20576); the Weizmann–Brazil Center for Research on Neurodegeneration at Weizmann Institute of Science; the Minerva Foundation, with funding from the Federal German Ministry for Education and Research; the ISF Legacy Heritage Fund (828/17); the Israel Science Foundation (135/16, 3497/21, 424/22, 425/22); United States - Israel Binational Science Foundation (#2021181); A research grant from the Anita James Rosen Foundation; Target ALS (118945); the Thierry Latran Foundation for ALS Research; the European Research Council under the European Union's Seventh Framework Program ([FP7/2007–2013]/ERC grant agreement number 617351); ERA-Net for Research Programs on Rare Diseases (eRARE FP7) via the Israel Ministry of Health; Dr Sydney Brenner and friends; Edward and Janie Moravitz; A. Alfred Taubman through IsrALS; Yeda-Sela; Yeda-CEO; the Israel Ministry of Trade and Industry; the Y. Leon Benoziyo Institute for Molecular Medicine; the Nella and Leon Benoziyo Center for Neurological Disease; the Kekst Family Institute for Medical Genetics; the David and Fela Shapell Family Center for Genetic Disorders Research; the Crown Human Genome Center; the Nathan, Shirley, Philip, and Charlene Vener New Scientist Fund; the Julius and Ray Charlestein Foundation; the Fraida Foundation; the Wolfson Family Charitable Trust; the Adelis Foundation; Merck (UK); M. Halphen; the estates of F. Sherr, L. Asseof, and L. Fulop; the Goldhirsh-Yellin Foundation; the Redhill Foundation–Sam and Jean

Rothberg Charitable Trust; Dr. Dvora and Haim Teitelbaum Endowment Fund; A research grant
from the Anita James Rosen Foundation. The ALS-Therapy Alliance, Motor Neuron Disease
Association (UK); this work was supported by the Motor Neuron Disease Association (MNDA)
839-791.
The Dementia Research Centre is supported by Alzheimer's Research UK, Brain Research
Trust, and The Wolfson Foundation. This work was supported by the NIHR Queen Square
Dementia Biomedical Research Unit, the NIHR UCL/H Biomedical Research Centre and the
Leonard Wolfson Experimental Neurology Centre (LWENC) Clinical Research Facility as well as
an Alzheimer's Society grant (AS-PG-16-007). JDR is supported by an MRC Clinician Scientist
Fellowship (MR/M008525/1) and has received funding from the NIHR Rare Disease
Translational Research Collaboration (BRC149/NS/MH). PF is supported by a Medical
Research Council Senior Clinical Fellowship, an MRC/MND LEW Fellowship, the NIHR UCLH
BRC and the Lady Edith Wolfson Fellowship scheme (MR/M008606/1 and MR/S006508/1).

NSY was supported by the Israeli Council for Higher Education (CHE) via the Weizmann Data
Science Research Center, by a research grant from the Estate of Tully and Michele Plesser and
by Maccabim Foundation. I.M. was supported by Teva Pharmaceutical Industries as part of the
Israeli National Network of Excellence in Neuroscience (fellowship no. 117941).

Authors' contribution
I.M., P.F., J.D.R. and E.H. conceived research.
I.M., N.S.Y. and E.H. analyzed the data.
A.M. and J.D.R. established cohort, gained ethical approval and collected human samples for
research.
Y.B., C.H. and I.S. assisted research.
I.M., N.S.Y., P.F., A.M., J.D.R. and E.H. wrote the manuscript, with comments and final
approval by all other authors.
J.D.W. provided resources for research and input in research development.
A.M. and J.D.R. are corresponding authors for cohorts and clinical data. P.F. and E.H. are
corresponding authors for all other facets of the work.
All authors read and approved the final manuscript.

Acknowledgements

We thank Vittoria Lombardi (UCL) for technical assistance. We acknowledge patients with FTD,
and healthy volunteers for their contribution and ALS biomarkers study co-workers for
biobanking, which has made this study possible (REC 09/H0703/27). We also thank the North
Thames Local Research Network (LCRN) for its support. EH is the Mondry Family Professorial
Chair and Head of the Nella and Leon Benoziyo Center for Neurological Diseases and of the
Andi and Larry Wolfe Center for Neuroimmunology and Neuromodulation.

Author's information

Not applicable

Appendix

IDs of 34 subjects removed due to age-based QC:

'CTRL_rep9', 'CTRL_rep10', 'CTRL_rep13', 'CTRL_rep19', 'CTRL_rep16', 'CTRL_rep18',
'CTRL_rep20', 'FTD30', 'CTRL_rep17', 'CTRL12', 'CTRL13', 'CTRL2', 'CTRL5', 'CTRL56',
'CTRL57', 'CTRL58', 'CTRL68', 'CTRL100', 'CTRL111', 'CTRL20', 'CTRL22', 'CTRL23',
'CTRL24', 'CTRL27', 'CTRL29', 'CTRL33', 'CTRL48', 'CTRL50', 'CTRL54', 'CTRL60','CTRL62',
'CTRL73', 'CTRL82', 'CTRL83'.

References

1. McKhann GM, Albert MS, Grossman M, Miller B, Dickson D, Trojanowski JQ, Work Group on Frontotemporal D, Pick's D: **Clinical and pathological diagnosis of frontotemporal dementia: report of the Work Group on Frontotemporal Dementia and Pick's Disease.** *Arch Neurol* 2001, **58:**1803-1809.
2. Seelaar H, Rohrer JD, Pijnenburg YA, Fox NC, van Swieten JC: **Clinical, genetic and pathological heterogeneity of frontotemporal dementia: a review.** *J Neurol Neurosurg Psychiatry* 2011, **82:**476-486.
3. Convery R, Mead S, Rohrer JD: **Review: Clinical, genetic and neuroimaging features of frontotemporal dementia.** *Neuropathol Appl Neurobiol* 2019, **45:**6-18.
4. Deleon J, Miller BL: **Frontotemporal dementia.** *Handb Clin Neurol* 2018, **148:**409-430.
5. DeJesus-Hernandez M, Mackenzie IR, Boeve BF, Boxer AL, Baker M, Rutherford NJ, Nicholson AM, Finch NA, Flynn H, Adamson J, et al: **Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS.** *Neuron* 2011, **72:**245-256.
6. Renton AE, Majounie E, Waite A, Simon-Sanchez J, Rollinson S, Gibbs JR, Schymick JC, Laaksovirta H, van Swieten JC, Myllykangas L, et al: **A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD.** *Neuron* 2011, **72:**257-268.
7. Skibinski G, Parkinson NJ, Brown JM, Chakrabarti L, Lloyd SL, Hummerich H, Nielsen JE, Hodges JR, Spillantini MG, Thusgaard T, et al: **Mutations in the endosomal ESCRTIII-complex subunit CHMP2B in frontotemporal dementia.** *Nat Genet* 2005, **37:**806-808.
8. Baker M, Mackenzie IR, Pickering-Brown SM, Gass J, Rademakers R, Lindholm C, Snowden J, Adamson J, Sadovnick AD, Rollinson S, et al: **Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17.** *Nature* 2006, **442:**916-919.
9. Borroni B, Bonvicini C, Alberici A, Buratti E, Agosti C, Archetti S, Papetti A, Stuani C, Di Luca M, Gennarelli M, Padovani A: **Mutation within TARDBP leads to frontotemporal dementia without motor neuron disease.** *Hum Mutat* 2009, **30:**E974-983.
10. Pottier C, Bieniek KF, Finch N, van de Vorst M, Baker M, Perkersen R, Brown P, Ravenscroft T, van Blitterswijk M, Nicholson AM, et al: **Whole-genome sequencing reveals important role for TBK1 and OPTN mutations in frontotemporal lobar degeneration without motor neuron disease.** *Acta Neuropathol* 2015, **130:**77-92.
11. Watts GD, Wymer J, Kovach MJ, Mehta SG, Mumm S, Darvish D, Pestronk A, Whyte MP, Kimonis VE: **Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein.** *Nat Genet* 2004, **36:**377-381.
12. Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT, Bruce J, Schuck T, Grossman M, Clark CM, et al: **Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis.** *Science* 2006, **314:**130-133.
13. Snowden JS, Neary D, Mann DM: **Frontotemporal dementia.** *Br J Psychiatry* 2002, **180:**140-143.
14. Olney NT, Spina S, Miller BL: **Frontotemporal Dementia.** *Neurol Clin* 2017, **35:**339-374.
15. Strong MJ, Abrahams S, Goldstein LH, Woolley S, McLaughlin P, Snowden J, Mioshi E, Roberts-South A, Benatar M, HortobaGyi T, et al: **Amyotrophic lateral sclerosis - frontotemporal spectrum disorder (ALS-FTSD): Revised diagnostic criteria.** *Amyotroph Lateral Scler Frontotemporal Degener* 2017, **18:**153-174.

16. Teunissen CE, Elias N, Koel-Simmelink MJ, Durieux-Lu S, Malekzadeh A, Pham TV,
Piersma SR, Beccari T, Meeter LH, Dopper EG, et al: **Novel diagnostic cerebrospinal**
fluid biomarkers for pathologic subtypes of frontotemporal dementia identified by
proteomics. *Alzheimers Dement (Amst)* 2016, **2:**86-94.
17. Sheikh-Bahaei N, Sajjadi SA, Pierce AL: **Current role for biomarkers in clinical**
diagnosis of Alzheimer disease and frontotemporal dementia. *Current treatment*
options in neurology 2017, **19:**46.
18. Meeter LH, Kaat LD, Rohrer JD, Van Swieten JC: **Imaging and fluid biomarkers in**
frontotemporal dementia. *Nature Reviews Neurology* 2017, **13:**406.
19. Meeter LHH, Vijverberg EG, Del Campo M, Rozemuller AJM, Donker Kaat L, de Jong
FJ, van der Flier WM, Teunissen CE, van Swieten JC, Pijnenburg YAL: **Clinical value**
of neurofilament and phospho-tau/tau ratio in the frontotemporal dementia
spectrum. *Neurology* 2018, **90:**e1231-e1239.
20. Feneberg E, Gray E, Ansorge O, Talbot K, Turner MR: **Towards a TDP-43-Based**
Biomarker for ALS and FTLD. *Mol Neurobiol* 2018, **55:**7789-7801.
21. Forgrave LM, Ma M, Best JR, DeMarco ML: **The diagnostic performance of**
neurofilament light chain in CSF and blood for Alzheimer's disease,
frontotemporal dementia, and amyotrophic lateral sclerosis: A systematic review
and meta-analysis. *Alzheimers Dement (Amst)* 2019, **11:**730-743.
22. Delaby C, Alcolea D, Carmona-Iragui M, Illan-Gala I, Morenas-Rodriguez E, Barroeta I,
Altuna M, Estelles T, Santos-Santos M, Turon-Sans J, et al: **Differential levels of**
Neurofilament Light protein in cerebrospinal fluid in patients with a wide range of
neurodegenerative disorders. *Sci Rep* 2020, **10:**9161.
23. van der Ende EL, Xiao M, Xu D, Poos JM, Panman JL, Jiskoot LC, Meeter LH, Dopper
EG, Papma JM, Heller C, et al: **Neuronal pentraxin 2: a synapse-derived CSF**
biomarker in genetic frontotemporal dementia. *J Neurol Neurosurg Psychiatry* 2020,
91:612-621.
24. Ashton NJ, Janelidze S, Al Khleifat A, Leuzy A, van der Ende EL, Karikari TK, Benedet
AL, Pascoal TA, Lleo A, Parnetti L, et al: **A multicentre validation study of the**
diagnostic value of plasma neurofilament light. *Nat Commun* 2021, **12:**3400.
25. Katisko K, Cajanus A, Huber N, Jaaskelainen O, Kokkola T, Karkkainen V, Rostalski H,
Hartikainen P, Koivisto AM, Hannonen S, et al: **GFAP as a biomarker in**
frontotemporal dementia and primary psychiatric disorders: diagnostic and
prognostic performance. *J Neurol Neurosurg Psychiatry* 2021, **92:**1305-1312.
26. Verde F, Otto M, Silani V: **Neurofilament Light Chain as Biomarker for Amyotrophic**
Lateral Sclerosis and Frontotemporal Dementia. *Front Neurosci* 2021, **15:**679199.
27. Wilson KM, Katona E, Glaria I, Carcole M, Swift IJ, Sogorb-Esteve A, Heller C,
Bouzigues A, Heslegrave AJ, Keshavan A, et al: **Development of a sensitive trial-**
ready poly(GP) CSF biomarker assay for C9orf72-associated frontotemporal
dementia and amyotrophic lateral sclerosis. *J Neurol Neurosurg Psychiatry* 2022,
93:761-771.
28. Katisko K, Cajanus A, Jaaskelainen O, Kontkanen A, Hartikainen P, Korhonen VE,
Helisalmi S, Haapasalo A, Koivumaa-Honkanen H, Herukka SK, et al: **Serum**
neurofilament light chain is a discriminative biomarker between frontotemporal
lobar degeneration and primary psychiatric disorders. *J Neurol* 2020, **267:**162-167.
29. Hansson O, Santillo AF, Meeter LH, Nilsson K, Landqvist Waldo M, Nilsson C, Blennow
K, van Swieten JC, Janelidze S: **CSF placental growth factor - a novel candidate**
biomarker of frontotemporal dementia. *Ann Clin Transl Neurol* 2019, **6:**863-872.
30. Al Shweiki MR, Steinacker P, Oeckl P, Hengerer B, Danek A, Fassbender K, Diehl-
Schmid J, Jahn H, Anderl-Straub S, Ludolph AC, et al: **Neurofilament light chain as a**

| 497 | | **blood biomarker to differentiate psychiatric disorders from behavioural variant frontotemporal dementia.** *J Psychiatr Res* 2019, **113:**137-140. |

blood biomarker to differentiate psychiatric disorders from behavioural variant
frontotemporal dementia. *J Psychiatr Res* 2019, **113:**137-140.

31.   Borroni B, Benussi A, Archetti S, Galimberti D, Parnetti L, Nacmias B, Sorbi S, Scarpini
E, Padovani A: **Csf p-tau181/tau ratio as biomarker for TDP pathology in**
frontotemporal dementia. *Amyotroph Lateral Scler Frontotemporal Degener* 2015,
16:86-91.

32.   Bourbouli M, Rentzos M, Bougea A, Zouvelou V, Constantinides VC, Zaganas I,
Evdokimidis I, Kapaki E, Paraskevas GP: **Cerebrospinal Fluid TAR DNA-Binding**
Protein 43 Combined with Tau Proteins as a Candidate Biomarker for Amyotrophic
Lateral Sclerosis and Frontotemporal Dementia Spectrum Disorders. *Dement*
Geriatr Cogn Disord 2017, **44:**144-152.

33.   Hu WT, Watts K, Grossman M, Glass J, Lah JJ, Hales C, Shelnutt M, Van Deerlin V,
Trojanowski JQ, Levey AI: **Reduced CSF p-Tau181 to Tau ratio is a biomarker for**
FTLD-TDP. *Neurology* 2013, **81:**1945-1952.

34.   Jiskoot LC, Panman JL, Meeter LH, Dopper EGP, Donker Kaat L, Franzen S, van der
Ende EL, van Minkelen R, Rombouts S, Papma JM, van Swieten JC: **Longitudinal**
multimodal MRI as prognostic and diagnostic biomarker in presymptomatic
familial frontotemporal dementia. *Brain* 2019, **142:**193-208.

35.   McCarthy J, Collins DL, Ducharme S: **Morphometric MRI as a diagnostic biomarker**
of frontotemporal dementia: A systematic review to determine clinical
applicability. *Neuroimage Clin* 2018, **20:**685-696.

36.   Niikado M, Chrem-Mendez P, Itzcovich T, Barbieri-Kennedy M, Calandri I, Martinetto H,
Serra M, Calvar J, Campos J, Russo MJ, et al: **Evaluation of Cerebrospinal Fluid**
Neurofilament Light Chain as a Routine Biomarker in a Memory Clinic. *J Gerontol A*
Biol Sci Med Sci 2019, **74:**442-445.

37.   Benussi A, Karikari TK, Ashton N, Gazzina S, Premi E, Benussi L, Ghidoni R, Rodriguez
JL, Emeršič A, Simrén J, et al: **Diagnostic and prognostic value of serum NfL and p-**
Tau(181) in frontotemporal lobar degeneration. *J Neurol Neurosurg Psychiatry* 2020,
91:960-967.

38.   Das S, Dewit N, Jacobs D, Pijnenburg YAL, In 't Veld S, Coppens S, Quaglia M, Hirtz C,
Teunissen CE, Vanmechelen E: **A Novel Neurofilament Light Chain ELISA Validated**
in Patients with Alzheimer's Disease, Frontotemporal Dementia, and Subjective
Cognitive Decline, and the Evaluation of Candidate Proteins for Immunoassay
Calibration. *Int J Mol Sci* 2022, **23**.

39.   Bellini S, Saraceno C, Benussi L, Squitti R, Cimini S, Ricci M, Canafoglia L, Coppola C,
Puoti G, Ferrari C, et al: **Plasma Small Extracellular Vesicles with Complement**
Alterations in GRN/C9orf72 and Sporadic Frontotemporal Lobar Degeneration.
Cells 2022, **11**.

40.   Chouliaras L, Thomas A, Malpetti M, Donaghy P, Kane J, Mak E, Savulich G, Prats-
Sedano MA, Heslegrave AJ, Zetterberg H, et al: **Differential levels of plasma**
biomarkers of neurodegeneration in Lewy body dementia, Alzheimer's disease,
frontotemporal dementia and progressive supranuclear palsy. *J Neurol Neurosurg*
Psychiatry 2022, **93:**651-658.

41.   Eratne D, Loi SM, Li QX, Stehmann C, Malpas CB, Santillo A, Janelidze S, Cadwallader
C, Walia N, Ney B, et al: **Cerebrospinal fluid neurofilament light chain differentiates**
primary psychiatric disorders from rapidly progressive, Alzheimer's disease and
frontotemporal disorders in clinical settings. *Alzheimers Dement* 2022.

42.   Krishnan G, Raitcheva D, Bartlett D, Prudencio M, McKenna-Yasek DM, Douthwright C,
Oskarsson BE, Ladha S, King OD, Barmada SJ, et al: **Poly(GR) and poly(GA) in**
cerebrospinal fluid as potential biomarkers for C9ORF72-ALS/FTD. *Nat Commun*
2022, **13:**2799.

43. Oeckl P, Anderl-Straub S, Von Arnim CAF, Baldeiras I, Diehl-Schmid J, Grimmer T,
Halbgebauer S, Kort AM, Lima M, Marques TM, et al: **Serum GFAP differentiates**
Alzheimer's disease from frontotemporal dementia and predicts MCI-to-dementia
conversion. *J Neurol Neurosurg Psychiatry* 2022.

44. Silva-Spinola A, Lima M, Leitao MJ, Duraes J, Tabuas-Pereira M, Almeida MR, Santana
I, Baldeiras I: **Serum neurofilament light chain as a surrogate of cognitive decline**
in sporadic and familial frontotemporal dementia. *Eur J Neurol* 2022, **29:**36-46.

45. Thijssen EH, Verberk IMW, Kindermans J, Abramian A, Vanbrabant J, Ball AJ,
Pijnenburg Y, Lemstra AW, van der Flier WM, Stoops E, et al: **Differential diagnostic**
performance of a panel of plasma biomarkers for different types of dementia.
Alzheimers Dement (Amst) 2022, **14:**e12285.

46. Coenen-Stass AML, Magen I, Brooks T, Ben-Dov IZ, Greensmith L, Hornstein E, Fratta
P: **Evaluation of methodologies for microRNA biomarker detection by next**
generation sequencing. *RNA Biol* 2018, **15:**1133-1145.

47. Magen I, Aharoni S, Yacovzada NS, Tokatly Latzer I, Alves CRR, Sagi L, Fattal-Valevski
A, Swoboda KJ, Katz J, Bruckheimer E, et al: **Muscle microRNAs in the cerebrospinal**
fluid predict clinical response to nusinersen therapy in type II and type III spinal
muscular atrophy patients. *Eur J Neurol* 2022, **29:**2420-2430.

48. Magen I, Yacovzada NS, Yanowski E, Coenen-Stass A, Grosskreutz J, Lu CH,
Greensmith L, Malaspina A, Fratta P, Hornstein E: **Circulating miR-181 is a**
prognostic biomarker for amyotrophic lateral sclerosis. *Nat Neurosci* 2021,
24:1534-1541.

49. Denk J, Oberhauser F, Kornhuber J, Wiltfang J, Fassbender K, Schroeter ML, Volk AE,
Diehl-Schmid J, Prudlo J, Danek A, et al: **Specific serum and CSF microRNA profiles**
distinguish sporadic behavioural variant of frontotemporal dementia compared
with Alzheimer patients and cognitively healthy controls. *PLoS One* 2018,
13:e0197329.

50. Grasso M, Piscopo P, Talarico G, Ricci L, Crestini A, Tosto G, Gasparini M, Bruno G,
Denti MA, Confaloni A: **Plasma microRNA profiling distinguishes patients with**
frontotemporal dementia from healthy subjects. *Neurobiol Aging* 2019.

51. Piscopo P, Grasso M, Puopolo M, D'Acunto E, Talarico G, Crestini A, Gasparini M,
Campopiano R, Gambardella S, Castellano AE, et al: **Circulating miR-127-3p as a**
Potential Biomarker for Differential Diagnosis in Frontotemporal Dementia. *J*
Alzheimers Dis 2018, **65:**455-464.

52. Sheinerman KS, Toledo JB, Tsivinsky VG, Irwin D, Grossman M, Weintraub D, Hurtig
HI, Chen-Plotkin A, Wolk DA, McCluskey LF, et al: **Circulating brain-enriched**
microRNAs as novel biomarkers for detection and differentiation of
neurodegenerative diseases. *Alzheimers Res Ther* 2017, **9:**89.

53. Schneider R, McKeever P, Kim T, Graff C, van Swieten JC, Karydas A, Boxer A, Rosen
H, Miller BL, Laforce R, Jr., et al: **Downregulation of exosomal miR-204-5p and miR-**
632 as a biomarker for FTD: a GENFI study. *J Neurol Neurosurg Psychiatry* 2018,
89:851-858.

54. Kmetzsch V, Anquetil V, Saracino D, Rinaldi D, Camuzat A, Gareau T, Jornea L, Forlani
S, Couratier P, Wallon D: **Plasma microRNA signature in presymptomatic and**
symptomatic subjects with C9orf72-associated frontotemporal dementia and
amyotrophic lateral sclerosis. *Journal of Neurology, Neurosurgery & Psychiatry* 2021,
92:485-493.

55. Sproviero D, Gagliardi S, Zucca S, Arigoni M, Giannini M, Garofalo M, Olivero M,
Dell'Orco M, Pansarasa O, Bernuzzi S, et al: **Different miRNA Profiles in Plasma**
Derived Small and Large Extracellular Vesicles from Patients with
Neurodegenerative Diseases. *Int J Mol Sci* 2021, **22.**

56. Tan YJ, Wong BYX, Vaidyanathan R, Sreejith S, Chia SY, Kandiah N, Ng ASL, Zeng L: **Altered Cerebrospinal Fluid Exosomal microRNA Levels in Young-Onset Alzheimer's Disease and Frontotemporal Dementia.** *J Alzheimers Dis Rep* 2021, **5:**805-813.

57. Muller M, Kuiperij HB, Versleijen AA, Chiasserini D, Farotti L, Baschieri F, Parnetti L, Struyfs H, De Roeck N, Luyckx J, et al: **Validation of microRNAs in Cerebrospinal Fluid as Biomarkers for Different Forms of Dementia in a Multicenter Study.** *J Alzheimers Dis* 2016, **52:**1321-1333.

58. Collins GS, Reitsma JB, Altman DG, Moons KG: **Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): the TRIPOD statement.** *Ann Intern Med* 2015, **162:**55-63.

59. Kohen R, Barlev J, Hornung G, Stelzer G, Feldmesser E, Kogan K, Safran M, Leshkowitz D: **UTAP: User-friendly Transcriptome Analysis Pipeline.** *BMC bioinformatics* 2019, **24:**154.

60. Kozomara A, Griffiths-Jones S: **miRBase: annotating high confidence microRNAs using deep sequencing data.** *Nucleic Acids Res* 2014, **42:**D68-73.

61. Love MI, Huber W, Anders S: **Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2.** *Genome Biol* 2014, **15:**550.

62. Elith J, Leathwick JR, Hastie T: **A working guide to boosted regression trees.** *J Anim Ecol* 2008, **77:**802-813.

63. Witten IH, Frank E, Hall MA, Pal CJ: **Ensemble Learning.** In *Data Mining (Fourth Edition).* Edited by Witten IH, Frank E, Hall MA, Pal CJ: Morgan Kaufmann; 2017: 479-501

64. Lundberg SM, Erion G, Chen H, DeGrave A, Prutkin JM, Nair B, Katz R, Himmelfarb J, Bansal N, Lee S-I: **From local explanations to global understanding with explainable AI for trees.** *Nature Machine Intelligence* 2020, **2:**56-67.

65. Liu F, Li T, Hu P, Dai L: **Upregulation of Serum miR-629 Predicts Poor Prognosis for Non-Small-Cell Lung Cancer.** *Dis Markers* 2021, **2021:**8819934.

66. Jingushi K, Ueda Y, Kitae K, Hase H, Egawa H, Ohshio I, Kawakami R, Kashiwagi Y, Tsukada Y, Kobayashi T, et al: **miR-629 Targets TRIM33 to Promote TGFbeta/Smad Signaling and Metastatic Phenotypes in ccRCC.** *Mol Cancer Res* 2015, **13:**565-574.

67. Ludwig N, Leidinger P, Becker K, Backes C, Fehlmann T, Pallasch C, Rheinheimer S, Meder B, Stähler C, Meese E, Keller A: **Distribution of miRNA expression across human tissues.** *Nucleic Acids Research* 2016, **44:**3865-3877.

68. Bu X, Li D, Wang F, Sun Q, Zhang Z: **Protective Role of Astrocyte-Derived Exosomal microRNA-361 in Cerebral Ischemic-Reperfusion Injury by Regulating the AMPK/mTOR Signaling Pathway and Targeting CTSB.** *Neuropsychiatr Dis Treat* 2020, **16:**1863-1877.

69. Hoerl AE, Kennard RW: **Ridge Regression: Biased Estimation for Nonorthogonal Problems.** *Technometrics* 1970, **12:**55-67.

70. Hoerl AE, Kennard RW: **Ridge Regression: Applications to Nonorthogonal Problems.** *Technometrics* 1970, **12:**69-82.

71. Chang WS, Wang YH, Zhu XT, Wu CJ: **Genome-Wide Profiling of miRNA and mRNA Expression in Alzheimer's Disease.** *Med Sci Monit* 2017, **23:**2721-2731.

72. He B, Chen W, Zeng J, Tong W, Zheng P: **MicroRNA-326 decreases tau phosphorylation and neuron apoptosis through inhibition of the JNK signaling pathway by targeting VAV1 in Alzheimer's disease.** *J Cell Physiol* 2020, **235:**480-493.

73. Ludwig N, Fehlmann T, Kern F, Gogol M, Maetzler W, Deutscher S, Gurlit S, Schulte C, von Thaler AK, Deuschle C, et al: **Machine Learning to Detect Alzheimer's Disease**

from Circulating Non-coding RNAs. *Genomics Proteomics Bioinformatics* 2019,
17:430-440.
74. Allach El Khattabi L, Heide S, Caberg J-H, Andrieux J, Doco Fenzy M, Vincent-Delorme
C, Callier P, Chantot-Bastaraud S, Afenjar A, Boute-Benejean O, et al: **16p13.11**
microduplication in 45 new patients: refined clinical significance and genotype–
phenotype correlations. *Journal of Medical Genetics* 2020, **57:**301-307.
75. Goncalves TF, Piergiorge RM, Dos Santos JM, Gusmao J, Pimentel MMG, Santos-
Reboucas CB: **Network Profiling of Brain-Expressed X-Chromosomal MicroRNA**
Genes Implicates Shared Key MicroRNAs in Intellectual Disability. *J Mol Neurosci*
2019, **67:**295-304.
76. Wingo TS, Yang J, Fan W, Min Canon S, Gerasimov ES, Lori A, Logsdon B, Yao B,
Seyfried NT, Lah JJ, et al: **Brain microRNAs associated with late-life depressive**
symptoms are also associated with cognitive trajectory and dementia. *NPJ Genom*
Med 2020, **5:**6.
77. Cogswell JP, Ward J, Taylor IA, Waters M, Shi Y, Cannon B, Kelnar K, Kemppainen J,
Brown D, Chen C, et al: **Identification of miRNA changes in Alzheimer's disease**
brain and CSF yields putative biomarkers and insights into disease pathways. *J*
Alzheimers Dis 2008, **14:**27-41.
78. Muller M, Kuiperij HB, Claassen JA, Kusters B, Verbeek MM: **MicroRNAs in**
Alzheimer's disease: differential expression in hippocampus and cell-free
cerebrospinal fluid. *Neurobiol Aging* 2014, **35:**152-158.
79. Nelson PT, Wang WX: **MiR-107 is reduced in Alzheimer's disease brain neocortex:**
validation study. *J Alzheimers Dis* 2010, **21:**75-79.
80. Prendecki M, Florczak-Wyspianska J, Kowalska M, Ilkowski J, Grzelak T, Bialas K,
Kozubski W, Dorszewska J: **APOE genetic variants and apoE, miR-107 and miR-650**
levels in Alzheimer's disease. *Folia Neuropathol* 2019, **57:**106-116.
81. Wang J, Chen C, Zhang Y: **An investigation of microRNA-103 and microRNA-107 as**
potential blood-based biomarkers for disease risk and progression of Alzheimer's
disease. *J Clin Lab Anal* 2020, **34:**e23006.
82. Yilmaz SG, Erdal ME, Ozge AA, Sungur MA: **Can Peripheral MicroRNA Expression**
Data Serve as Epigenomic (Upstream) Biomarkers of Alzheimer's Disease? *OMICS*
2016, **20:**456-461.
83. Wang WX, Rajeev BW, Stromberg AJ, Ren N, Tang G, Huang Q, Rigoutsos I, Nelson
PT: **The expression of microRNA miR-107 decreases early in Alzheimer's disease**
and may accelerate disease progression through regulation of beta-site amyloid
precursor protein-cleaving enzyme 1. *J Neurosci* 2008, **28:**1213-1223.
84. Lindberg RL, Hoffmann F, Mehling M, Kuhle J, Kappos L: **Altered expression of miR-**
17-5p in CD4+ lymphocytes of relapsing-remitting multiple sclerosis patients. *Eur*
J Immunol 2010, **40:**888-898.
85. Yang D, Wang WZ, Zhang XM, Yue H, Li B, Lin L, Fu J: **MicroRNA expression**
aberration in Chinese patients with relapsing remitting multiple sclerosis. *J Mol*
Neurosci 2014, **52:**131-137.
86. Honardoost MA, Kiani-Esfahani A, Ghaedi K, Etemadifar M, Salehi M: **miR-326 and**
miR-26a, two potential markers for diagnosis of relapse and remission phases in
patient with relapsing-remitting multiple sclerosis. *Gene* 2014, **544:**128-133.
87. Niwald M, Migdalska-Sek M, Brzezianska-Lasota E, Miller E: **Evaluation of Selected**
MicroRNAs Expression in Remission Phase of Multiple Sclerosis and Their
Potential Link to Cognition, Depression, and Disability. *J Mol Neurosci* 2017,
63:275-282.

88.   Regev K, Healy BC, Paul A, Diaz-Cruz C, Mazzola MA, Raheja R, Glanz BI, Kivisakk P,
Chitnis T, Jagodic M, et al: **Identification of MS-specific serum miRNAs in an**
international multicenter study. *Neurol Neuroimmunol Neuroinflamm* 2018, **5:**e491.

89.   Sharaf-Eldin WE, Kishk NA, Gad YZ, Hassan H, Ali MAM, Zaki MS, Mohamed MR,
Essawi ML: **Extracellular miR-145, miR-223 and miR-326 expression signature**
allow for differential diagnosis of immune-mediated neuroinflammatory diseases.
J Neurol Sci 2017, **383:**188-198.

90.   Baulina N, Kulakova O, Kiselev I, Osmak G, Popova E, Boyko A, Favorova O: **Immune-**
related miRNA expression patterns in peripheral blood mononuclear cells differ in
multiple sclerosis relapse and remission. *J Neuroimmunol* 2018, **317:**67-76.

91.   Dolati S, Aghebati-Maleki L, Ahmadi M, Marofi F, Babaloo Z, Ayramloo H, Jafarisavari Z,
Oskouei H, Afkham A, Younesi V, et al: **Nanocurcumin restores aberrant miRNA**
expression profile in multiple sclerosis, randomized, double-blind, placebo-
controlled trial. *J Cell Physiol* 2018, **233:**5222-5230.

92.   Regev K, Healy BC, Khalid F, Paul A, Chu R, Tauhid S, Tummala S, Diaz-Cruz C,
Raheja R, Mazzola MA, et al: **Association Between Serum MicroRNAs and Magnetic**
Resonance Imaging Measures of Multiple Sclerosis Severity. *JAMA Neurol* 2017,
74:275-285.

Main table and figures

	Control	FTD
Number of subjects (% males)	125 (32%)	168 (65.5%)
UCL controls	48 (45.8%)	
Queen Mary Hospital controls	77 (23.4%)	
Age at enrolment	59.5±10.2 yr.	65.8±8.1 yr.
UCL controls	65.6±7.3 yr.	
Queen Mary Hospital controls	55.7±10.0 yr	
Age of onset (1st reported symptoms)		60.3±8.3 yr.
Disease duration at enrolment		5.5±3.4 yr.
FTD clinical subtype (bvFTD/PNFA/SD/FTD-ALS/others)		81/40/28/5/14
FTD Mutation carriers (C9ORF72/MAPT/GRN/TBK1)		18/13/13/2
Likely FTD pathology (TDP-43/Tau)		63/18

Table 1. Summary of demographic and clinical characteristics of participants suffering from FTD and control samples. bvFTD: behavioural FTD; PNFA: progressive nonfluent aphasia; SD: semantic dementia. Mean±SD.

Predictor	Single Feature AUC
miR-423-5p	0.69
miR-125b-5p	0.69
miR-26a-5p	0.68
miR-107	0.68
miR-185-5p	0.64
miR-629-5p	0.62
let-7d-3p	0.61
miR-379-5p	0.61
miR-361-5p	0.6
let-7c-5p	0.6
miR-326	0.58
miR-378a-3p	0.56
miR-484	0.55

721 **Table 2. Predictive power of selected miRNA features, when used as a single predictor for FTD on**
722 **held-out data.** Among the most predictive features are miRNAs expressed in the brain, such as miR-26a-
723 5p, miR-125b-5p and let-7c-5p.

724
Figure 1. miRNA signature associated with FTD. MA plot of differential miRNA expression in plasma of
patients with FTD vs non-neurodegenerative healthy controls in the **(A)** total cohort of FTD patients and
controls (N=168 and N=125, respectively). **(B)** C9ORF72 mutations carriers only (N=18) vs healthy
controls (N=125). **(C)** Female patients with FTD and healthy female controls (N=58 and N=85,
respectively) **(D)** male patients with FTD and healthy male controls (N=110 and N=40, respectively). Log
2 transformed fold change (y-axis), against mean miRNA abundance (x-axis). Red: significantly changed
miRNAs (adjusted p<0.05, Wald test). Black: miRNAs showing insignificant change.

732
Figure 2: Diagnosis of FTD by a distinctive cell free miRNA signature. **(A)** Mean accuracy under 3-
fold cross validation (AUC ROC, y-axis) as a function of the number of plasma miRNAs used in the FTD
prediction model. Increasing numbers of miRNA features (x-axis) successively selected in the recursive
feature elimination process reveals a saturation at 13 features (red line). **(B)** ROC curves in the training
set: true positive rate (y-axis) vs. false positive rate (x-axis). Mean values and variance of data from 219
samples with 3-fold cross validation. Mean AUC 0.93 ± 0.02. 95% CI is 0.91-0.95. **(C)** Performance and
generalizability on replication held-out data revealed by an ROC curve with AUC of 0.9. **(D)** Reliability
diagram, plotting truly observed fraction of cases (upper plot, y-axis) vs. predicted probability by the
prediction model (upper plot, x-axis), in five probability bins, reveals a sufficiently calibrated model on the
held-out set. Lower plot shows the number of individuals at each of the five predicted probability bins. **(E)**
Confusion matrix showing the prediction errors on held out dataset. At a probability threshold of 0.6, we
observed 0.87 Negative predictive value (NPV), 0.8 Positive Predictive Value (PPV/precision), 0.85 recall
(sensitivity) and 0.83 specificity. In addition, a 0.17 False Positive Rate is obtained over 0.13 False
Omission Rate and 0.2 false discovery rate. **(F)** AUC ROC of a model trained with only a subset of top 13
most predictive features, reveals a stable performance with the selected final features.

748
Figure 3: The contribution of individual miRNAs to the predictor of FTD diagnosis. (A) Mean
absolute SHapley Additive exPlanations (SHAP) values break down the impact of specific miRNAs on
FTD disease non-linear predictor output in the held-out cohort. **(B)** Illustration of the relationship between
the miRNA levels (low – blue to high – red), SHAP values and the impact on the prediction in the held-out
cohort. Positive or negative SHAP value lead the model to a more likely FTD or healthy control
predictions, respectively.

755
Figure 4. Distribution of the top 13 miRNA predictors in patients with FTD and controls. Box plots
with complement <u>scatter</u> plots of the 13 miRNA features predicting FTD, depicting expression values of all
cohort along with distribution of each miRNA. Blue dots represent the levels of a given miRNA measured
in healthy control participants. Red dots represent the levels of a given miRNA measured in patients with
FTD. Box – two central data quartiles, with a line at the median (Q2). Whiskers extend to show the rest of
the distribution, except for points that are determined to be outliers using a method that is a function of
the inter-quartile range.

Figure 5. AUC values for different miRNA classifiers for discriminating FTD vs controls in the
held-out data. The classifiers were either the 13 selected in the FTD model in our data, a combination of
miR-34a-5p, miR-345-5p, miR-200c-3p and miR-10a-3p [from [54]], or a combination of miR-335/let-7e,
miR-99b/let-7e and miR-9-3p/miR-181a [from [52]];

Supplementary tables and figures

Group Name	Before Exclusion				After Exclusion		
	Age [95% CI]	Sex	Mean Age	Group Size	Age [95% CI]	Mean Age	Group Size
controls total (n=158)	53.8±14.5, 95% CI [51.5, 56.1]	F	54.0	103	59.5±10.2, 95% CI [57.7, 61.3]	58.4	85
		M	53.4	55		61.7	40
UCL controls (n=56)	61.0± 13.3, 95% CI [57.4, 64.5]	F	61.1	30	65.55± 7.3, 95% CI [63.4, 67.7]	65.6	26
		M	60.8	26		65.5	22
Queen Mary Hospital controls (n=102)	49.9±13.7, 95% CI [47.2, 52.6]	F	51.1	73	55.7±10.0, 95% CI [53.4, 58.0]	55.3	59
		M	46.8	29		57.0	18
FTD cases (n=169)	65.6± 8.3, 95% CI [64.4, 67.0]	F	66.8	59	65.8±8.1, 95% CI [64.6, 67.0]	67.4	58
		M	65.0	110		65.0	110

Supplementary Table 1. Age and sex characteristics of the cohort and exclusion by age of 34 individuals that were below 40 years of age during blood collection.

773 **Supplementary Figure 1. t-SNE analysis of control subjects from Queen Mary Hospital (blue) and**

774 **from UCL (red).** Similarity of the two control groups suggests they could have been taken from a single

775 distribution which is justified further by an associated Kullback–Leibler divergence value of 0.293, a

776 measure of the difference between two probability distributions.

777
Supplementary Figure 2. Diagnosis of FTD by a logistic regression model. *(A)* ROC curves in the
training set: true positive rate (y-axis) vs. false positive rate (x-axis). Mean values and variance of data
from 219 samples with 3-fold cross validation. Mean AUC 0.90 ± 0.04. 95% CI is 0.86-0.94. **(B)**
Performance and generalizability on held-out data revealed by a ROC curve with AUC of 0.88. **(C)**
Reliability diagram, plotting truly observed fraction of cases (upper plot, y-axis) vs. predicted probability by
the prediction model (upper plot, x-axis), in five probability bins, reveals a sufficiently calibrated model on
the held-out set. Lower plot shows the number of individuals at each of the five predicted probability bins.
(D) Confusion matrix showing the prediction errors on held out dataset. At a probability threshold of 0.6,
we observed 0.81 Negative predictive value (NPV), 0.81 Positive Predictive Value (PPV/precision), 0.76
recall (sensitivity) and 0.85 specificity. In addition, 0.15 False Positive Rate is obtained, over 0.19 False
Omission Rate and 0.19 false discovery rate.

Supplementary Figure 3. Levels of 13 miRNA predictors in different FTD subtypes. miRNA levels for
PNFA (progressive nonfluent aphasia), SD (semantic dementia), behavioral FTD (bvFTD) and the
following subtypes: primary progressive aphasia, corticobasal syndrome, progressive supranuclear palsy
and FTD with motor neuron disease, commonly referred to as "Other". Box plot with two central data
quartiles, with a line at the median (Q2). Whiskers extend to show the rest of the distribution, except for
points that are determined to be outliers using a method that is a function of the inter-quartile range. Data
were analyzed by one-way ANOVA. Post-hoc Bonferroni was conducted only for miR-107 **(C)** and miR-
26a-5p **(F)** which showed significant differences in ANOVA. Significant pairwise differences in miR-107
levels were found between other FTD subtypes and both bvFTD (p=0.01) and SD (p=0.02). Significant
pairwise differences in miR-26a were found between other FTD subtypes and both bvFTD (p=0.04) and
PNFA (p=0.02).

801
802 **Supplementary Figure 4. Levels of 13 miRNA predictors in mutations carriers.** miRNA levels for
803 FTD patients without known FTD mutations, or with mutations in C9ORF72, progranulin (GRN), tau
804 (MAPT) and TBK1. Box plot with two central data quartiles, with a line at the median (Q2). Whiskers
805 extend to show the rest of the distribution, except for points that are determined to be outliers using a
806 method that is a function of the inter-quartile range. Data were analyzed by one-way ANOVA.